Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan.
J Gastroenterol. 2017 Aug;52(8):940-954. doi: 10.1007/s00535-016-1298-6. Epub 2017 Jan 6.
Palmitic acid is an important risk factor for the pathogenesis of non-alcoholic steatohepatitis (NASH), but changes in palmitic acid intestinal absorption in NASH are unclear. The aim of this study was to clarify changes in palmitic acid intestinal absorption and their association with the pathogenesis of NASH.
A total of 106 participants were recruited to the study, of whom 33 were control subjects (control group), 32 were patients with NASH Brunt stage 1-2 [early NASH (e-NASH)], and 41 were patients with NASH Brunt stage 3-4 [advanced NASH (a-NASH)]. C-labeled palmitate was administered directly into the duodenum of all participants by gastrointestinal endoscopy. Breath CO levels were measured to quantify palmitic acid absorption, and serum Apolipoprotein B-48 (ApoB-48) concentrations were measured after a test meal to quantify absorbed chylomicrons. Expressions of fatty acid (FA) transporters were also examined. The associations of breath CO levels with hepatic steatosis, fibrosis and insulin resistance was evaluated using laboratory data, elastography results and liver histology findings.
Overall, CO excretion was significantly higher in e-NASH patients than in the control subjects and a-NASH patients (P < 0.01). e-NASH patients had higher serum ApoB-48 levels, indicating increased palmitic acid transport via chylomicrons in these patients. Jejunal mRNA and protein expressions of microsomal triglyceride transfer protein and cluster of differentiation 36 were also increased in both NASH patient groups. The CO excretion of e-NASH patients was significantly correlated with the degree of hepatic steatosis, fibrosis and insulin resistance (P = 0.005, P < 0.001, P = 0.019, respectively).
Significantly upregulated palmitic acid absorption by activation of its transporters was evident in patients with NASH, and clinical progression of NASH was related to palmitic acid absorption. These dietary changes are associated with the onset and progression of NASH.
棕榈酸是导致非酒精性脂肪性肝炎(NASH)发病的重要危险因素,但 NASH 患者棕榈酸肠道吸收的变化尚不清楚。本研究旨在阐明棕榈酸肠道吸收的变化及其与 NASH 发病机制的关系。
共有 106 名参与者被纳入研究,其中 33 名是对照组(对照组),32 名是 NASH Brunt 1-2 期患者(早期 NASH[e-NASH]),41 名是 NASH Brunt 3-4 期患者(晚期 NASH[a-NASH])。通过胃肠内镜将 C 标记的棕榈酸直接注入所有参与者的十二指肠。测量呼气 CO 水平以量化棕榈酸吸收,并在测试餐后测量血清载脂蛋白 B-48(ApoB-48)浓度以量化吸收的乳糜微粒。还检查了脂肪酸(FA)转运蛋白的表达。使用实验室数据、弹性成像结果和肝组织学检查结果评估呼气 CO 水平与肝脂肪变性、纤维化和胰岛素抵抗的关系。
总的来说,e-NASH 患者的 CO 排泄量明显高于对照组和 a-NASH 患者(P < 0.01)。e-NASH 患者的血清 ApoB-48 水平较高,表明这些患者通过乳糜微粒转运的棕榈酸增加。微团甘油三酯转移蛋白和分化群 36 的空肠 mRNA 和蛋白表达在两组 NASH 患者中也增加。e-NASH 患者的 CO 排泄量与肝脂肪变性、纤维化和胰岛素抵抗的严重程度显著相关(P = 0.005、P < 0.001、P = 0.019)。
在 NASH 患者中,通过其转运蛋白的激活明显上调了棕榈酸的吸收,NASH 的临床进展与棕榈酸的吸收有关。这些饮食变化与 NASH 的发生和进展有关。